PL2486051T3 - Preparat farmaceutyczny zawierający rekombinowaną hcg - Google Patents

Preparat farmaceutyczny zawierający rekombinowaną hcg

Info

Publication number
PL2486051T3
PL2486051T3 PL10763000T PL10763000T PL2486051T3 PL 2486051 T3 PL2486051 T3 PL 2486051T3 PL 10763000 T PL10763000 T PL 10763000T PL 10763000 T PL10763000 T PL 10763000T PL 2486051 T3 PL2486051 T3 PL 2486051T3
Authority
PL
Poland
Prior art keywords
pharmaceutical preparation
recombinant hcg
hcg
recombinant
pharmaceutical
Prior art date
Application number
PL10763000T
Other languages
English (en)
Polish (pl)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL2486051T3 publication Critical patent/PL2486051T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL10763000T 2009-10-05 2010-10-04 Preparat farmaceutyczny zawierający rekombinowaną hcg PL2486051T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
EP10763000.6A EP2486051B1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Publications (1)

Publication Number Publication Date
PL2486051T3 true PL2486051T3 (pl) 2020-09-07

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10763000T PL2486051T3 (pl) 2009-10-05 2010-10-04 Preparat farmaceutyczny zawierający rekombinowaną hcg

Country Status (25)

Country Link
US (5) US8975226B2 (enExample)
EP (2) EP2486051B1 (enExample)
JP (6) JP6176924B2 (enExample)
KR (7) KR102213154B1 (enExample)
CN (1) CN107050434B (enExample)
AR (2) AR079876A1 (enExample)
AU (1) AU2010304922B2 (enExample)
BR (1) BR112012007990A2 (enExample)
CA (1) CA2776790A1 (enExample)
DK (1) DK2486051T3 (enExample)
ES (2) ES3036152T3 (enExample)
HR (1) HRP20200941T1 (enExample)
HU (1) HUE050793T2 (enExample)
IL (3) IL218548A (enExample)
IN (1) IN2012DN02073A (enExample)
JO (1) JOP20200039A1 (enExample)
LT (1) LT2486051T (enExample)
MX (1) MX2012003951A (enExample)
PL (1) PL2486051T3 (enExample)
PT (1) PT2486051T (enExample)
RS (1) RS60413B1 (enExample)
RU (2) RU2724528C2 (enExample)
SI (1) SI2486051T1 (enExample)
TW (2) TWI532495B (enExample)
WO (1) WO2011042688A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104919046A (zh) 2012-12-10 2015-09-16 生化学工业株式会社 新重组因子c、其制造方法、及内毒素的测定法
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
WO2019211153A1 (en) * 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
AU2021215893A1 (en) * 2020-02-05 2022-08-25 Novartis Ag CHO cell expressing IL-15 heterodimers
CN116199742B (zh) * 2022-07-06 2025-01-24 华兰基因工程有限公司 一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法
TWD234354S (zh) * 2023-09-19 2024-10-21 日商富士股份有限公司 (日本) 轉移輔助機
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69524456T2 (de) * 1995-03-21 2002-08-01 Applied Research Systems Flüssige hcg-formulierungen
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU747179B2 (en) 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CA2372714A1 (en) * 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
PL205149B1 (pl) * 2000-02-22 2010-03-31 Serono Lab Sposób przygotowania rekombinowanej hCG
HRP20040087A2 (en) 2001-09-12 2004-12-31 Applied Research Systems USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
EA008220B1 (ru) * 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
JP2006522151A (ja) * 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
CA2522345A1 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
JP4518464B2 (ja) 2003-06-30 2010-08-04 ミヨシ油脂株式会社 紙類処理剤及び紙類
DK1654353T3 (da) * 2003-08-18 2013-08-26 Glycotope Gmbh Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) * 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
JP2009504985A (ja) 2005-08-15 2009-02-05 シーメンス ヴィディーオー オートモーティヴ コーポレイション ディーゼル車排気への炭化水素計量弁
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CA3163525A1 (en) * 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
KR101804479B1 (ko) 2017-12-05
JOP20200039A1 (ar) 2022-10-30
ES2798258T3 (es) 2020-12-10
KR20190028823A (ko) 2019-03-19
JP6580104B2 (ja) 2019-09-25
KR101987982B1 (ko) 2019-06-11
AR125991A2 (es) 2023-08-30
TW201632198A (zh) 2016-09-16
KR102213154B1 (ko) 2021-02-05
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
US20200247863A1 (en) 2020-08-06
AR079876A1 (es) 2012-02-29
JP2013506708A (ja) 2013-02-28
AU2010304922A1 (en) 2012-03-29
RU2016118236A3 (enExample) 2019-09-18
PT2486051T (pt) 2020-06-17
US20220340634A1 (en) 2022-10-27
RU2588650C2 (ru) 2016-07-10
RU2016118236A (ru) 2018-10-29
KR20210141771A (ko) 2021-11-23
US10526390B2 (en) 2020-01-07
US8975226B2 (en) 2015-03-10
KR20230012104A (ko) 2023-01-25
CN107050434A (zh) 2017-08-18
MX2012003951A (es) 2012-05-29
JP2018076296A (ja) 2018-05-17
JP2020000246A (ja) 2020-01-09
CN107050434B (zh) 2021-07-27
KR20190067256A (ko) 2019-06-14
IL267556A (en) 2019-08-29
JP2021176867A (ja) 2021-11-11
JP6310440B2 (ja) 2018-04-11
CN102549011A (zh) 2012-07-04
IL250733A0 (en) 2017-04-30
US11292824B2 (en) 2022-04-05
LT2486051T (lt) 2020-07-10
KR102489143B1 (ko) 2023-01-13
US9676835B2 (en) 2017-06-13
TW201113030A (en) 2011-04-16
JP2016074680A (ja) 2016-05-12
IN2012DN02073A (enExample) 2015-08-21
EP2486051B1 (en) 2020-03-25
KR20170133531A (ko) 2017-12-05
BR112012007990A2 (pt) 2017-07-25
DK2486051T3 (da) 2020-06-22
US20140249082A1 (en) 2014-09-04
HUE050793T2 (hu) 2021-01-28
KR20210014767A (ko) 2021-02-09
ES3036152T3 (en) 2025-09-15
EP3611185A1 (en) 2020-02-19
JP2023075144A (ja) 2023-05-30
US12234272B2 (en) 2025-02-25
SI2486051T1 (sl) 2020-08-31
AU2010304922B2 (en) 2014-11-06
JP7196244B2 (ja) 2022-12-26
WO2011042688A1 (en) 2011-04-14
JP6176924B2 (ja) 2017-08-09
EP2486051A1 (en) 2012-08-15
RU2724528C2 (ru) 2020-06-23
JP7292153B2 (ja) 2023-06-16
IL218548A (en) 2017-03-30
RU2012112907A (ru) 2013-11-10
US20180030107A1 (en) 2018-02-01
HRP20200941T1 (hr) 2020-09-18
IL218548A0 (en) 2012-05-31
EP3611185B1 (en) 2025-04-30
TWI532495B (zh) 2016-05-11
US20130023476A1 (en) 2013-01-24
IL250733B (en) 2019-07-31
RS60413B1 (sr) 2020-07-31
CA2776790A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
IL267556A (en) A pharmaceutical preparation containing recombinant hcg
IL215451A0 (en) Pharmaceutical composition
ZA201200719B (en) Pharmaceutical formulation
GB0909680D0 (en) Dosage form
IL220097A (en) Pharmaceutical preparation containing oligopeptides
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
PL2496596T3 (pl) Peptydy terapeutyczne
ZA201104348B (en) Pharmaceutical preparation
GB0810615D0 (en) Novel pharmaceutical
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0815972D0 (en) Pharmaceutical preparation
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
HRP20141173T1 (hr) Medikament koji sadrži miramistin
GB0922537D0 (en) Pharmaceutical preparation
GB0919650D0 (en) Pharmaceutical composition
GB201115179D0 (en) Pharmaceutical preparation
GB201115173D0 (en) Pharmaceutical preparation
GB0906971D0 (en) Pharmaceutical preparation
GB0910772D0 (en) Pharmaceutical
PL390620A1 (pl) Preparat farmaceutyczny
GB0909494D0 (en) Neuroprotective peptide
IL214496A0 (en) Short b-defensin-derived peptides
GB0901902D0 (en) Medicament
GB0903318D0 (en) Medicament